About this episode

This episode discusses the promising results of brepocitinib in treating dermatomyositis and its potential approval.

Great trial this week looking at brepocitinib in dermatomyositis. Looks like a winner, expect it will be approved. Where it fits in our approach to IIM is an open question, but nice to have another option. Study: https://www.nejm.org/doi/10.1056/NEJMoa2503531 JC Companion: https://autoimmunedevreport.substack.com/

More episodes of The Evidence Based Rheumatology Podcast

• E133: Obinutuzumab for SLE (ALLEGORY) · March 19, 2026 · 15 min
• E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE) · March 5, 2026 · 14 min
• E131: A Sham-Controlled Sham of a Trial: RESET-RA · January 21, 2026 · 15 min
• E130: Telitacicept for SLE · December 22, 2025 · 13 min
• E129: Long Term Routine Laboratory Monitoring in RA · December 4, 2025 · 15 min
• E128: Nerandomilast for Autoimmune ILD (FIBRONEER-ILD) · November 12, 2025 · 19 min

Explore listener stats, chart rankings, contacts and more on the The Evidence Based Rheumatology Podcast podcast page.